METHOD FOR DETECTION OF PRIMARY REFRACTORY FORM OF MULTIPLE MYELOMA AT THE DISEASE ONSET Russian patent published in 2021 - IPC C12Q1/68 C12N15/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, namely to oncohematology, and applies to detection of prognostic molecular genetic criteria for primary refractory multiple myeloma (MM) at the disease onset. The method for predicting the primary refractory form of MM includes isolating genomic DNA from leukocytes of the peripheral venous blood of the patients prior to beginning first-line induction therapy, genotyping the IL10 gene polymorphism at the -1082 mutation point, estimating the distribution of the identified alleles and genotypes, analysing the response to therapy throughout the entire observation period. If a mutant allele A of the IL10 G1082A gene is detected in a hetero- and homozygous state, a high risk of non-response to induction therapy is predicted.

EFFECT: invention allows to obtain new additional criteria for the aspects of the course of MM in the early stages of the disease before the start of the chemotherapy plan to select risk-adapted methods of treatment.

1 cl, 1 dwg, 4 tbl, 3 ex